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ABSTRACT:
Among the common neurological disorders worldwide, Parkinson’s disease has a major share. Currently, only
symptomatic therapies are available for it without any approved neuromodulation drugs as all the previously done
disease modification trials have failed. There is a dire need for such therapies. Disease modification trials include all
types of intervention targeting the degeneration process which underlies the disease process and thus slows it down
or the treatment aim to regenerate or replace the neurons which are lost. There are many reasons for the failure of
trials. This review emphasize the need for disease modification trials, causes of failure of trials, few prominent
previously failed trails and review on-going clinical trials for disease modification. The aim of this review article is to
highlight the importance and utmost need of development of neuroprotective agents for Parkinson’s disease through
future research.
KEY WORDS: parkinson’s disease, Neuroprotective therapies, Neuromodulation therapies for Parkinson’s disease.

Introduction
Parkinson’s disease (PD) is the second most common
neurodegenerative process after Alzheimer’s disease. It
was introduced by Dr. James Parkinson in 1817, who
called him as a “shaking palsy.” 1 It is a chronic,
progressive neurodegenerative disorder characterized
by clinical features involving both motor and non-motor
systems. Consequently, a significant clinical impact is
seen on patients, families, and caregivers of patients as
a result of limited patients’ mobility leading to
additional social and economic burden. The presence
of Non-motor features is due to neuronal loss in
nondopaminergic areas while the motor symptoms of
PD are attributed to the striatal dopaminergic neurons
loss. Parkinsonism is a symptom complex used to
describe the motor features of PD, which include
bradykinesia, muscular rigidity and resting tremor.
Among the list of causes of Parkinsonism which causes
secondary Parkinsonism, Idiopathic Parkinson is the
major cause of Parkinsonism 2 .Literature search shows
that non-motor presentations of Parkinson appear far
before the motor feature which is the time when
pathogenesis of Parkinson start and is the focus of
neuromodulation therapies.3 Currently, no long term
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and neuroprotective therapies are available. There is
the utmost need of time to search for the disease
modification therapies to meet the challenge of
neurodegeneration. By searching literature, we are
hopeful that such strategies will lead to the
development of disease modifying therapies 4.This is
supported by previous studies that shows that
identification of decreased neuronal loss will be most
fruitful 5. Our aim of writing this review article is to
critically analyze the clinical trials which have been
done and are ongoing currently in this field.
NEED OF DISEASE MODIFICATION TRIALS IN
PARKINSONS DISEASE
Unfortunately, despite the promise of many therapies in
preclinical trials, to date there is failure of any available
approved drug for this purpose. Inevitable factors
include irresistible dependency on animal models
which are mostly toxin based along with insufficient
knowledge of underlying pathogenesis6. Other
drawbacks in previous clinical trials are discussed
below which should be optimized through proper study
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designs to get more successful results7.
MATERIALS AND METHODS
Our article is narrative review. A detailed evaluation of articles published within last twenty five years on disease
modification trials in Parkinson disease was undertaken. It included following steps: (1) a systematic search of review
articles, (2) a critical appraisal of identified studies. Sources included mainly PubMed articles and clinicaltrials.gov.
Using the key words mentioned above. To our knowledge, no previous article on this topic is available from Pakistan,
which is our rationale for writing this review.
TARGETS FOR NEUROPROTECTION
The crucial steps in PD pathogenesis are outlined in FIGURE -1 while the targets of disease modification in Parkinsons
disease and complex interaction of these steps which give rise to PD pathology and its neurodegeneration are
presented in FIGURE 2.
WHY CLINICAL TRIALS OF PARKINSON DISEASE MODIFICATION FAILED?
There is no neuromodulation treatment yet in Parkinson disease as per American academy of Neurology, recent
practice parameter 8.
It’s worth appreciating to have such trials on board but inevitable step is to keep in mind the numerous other
approaches that have failed. There are many reasons for failures.(FIGURE 3)
1. Insufficient understanding of PD pathogenesis as it undoubtedly represents more than one disease.
2. Ongoing dependence on animal models which are poorly predictive of neuroprotection in humans.
3. Need of better biomarkers for fruitful evaluation of therapy outcomes.
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FIGURE 1: Mechanisms of PD pathogenesis
4. Inaviodable negative outcome even in well-designed and rational trials, treatments may still fail.
5. Lack of financial and institutional supports as well as inadequate research grants.
FAILED CLINICAL TRIALS
ELLDOPA trial (earlier verus later L-Dopa trial) was published in 1999.Levodopa (L-dopa) is the well-established
and most efficacious symptomatic therapy in Parkinson. Due to the well understood role of dopamine catabolism
producing free radicals, the hope generated for the neuroprotective role of levodopa 9,10 as a variety of preclinical data
has predicted its neuroprotective effect 11,12.
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FIGURE 2: Targets of disease modification in Parkinsons disease
Placebo or L- dopa was given to at dose of 150 mg,300 mg or 600 mg per day to 361 patients for 40 weeks. It was
followed by a washout period of 2 weeks. No significant difference was shown between the group of patients who were
treated early with levodopa (n = 222) or in a delayed fashion (n = 223) in Unified Parkinson’s Disease Rating Scale
(UPDRS) score (P = .44)13.
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FIGURE 3: Main determinants for previous PD Neuroprotection trials failures
The results are shown in (Figure 4). The drawback of the study leading to controversial interpretation was ambiguity
whether the effects of L-dopa outlasted the chosen 2 weeks washout period in the study which affects the results. The
reliability of these neuroimaging techniques as measures for PD progression are still uncertain 14,15
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FIGURE 4 : RESULTS OF ELLDOPA STUDY
Another trial was conducted on 800 patients in 1987 on Deprenyl and Tocopherol for the treatment of early Parkinson's
disease. Results showed no significant effect. Deprenyl is a monoamine oxidase inhibitor while tocopherol is a vitamin
E component acting as a free radical trap.The beneficial effect of deprenyl remains unclear based on the outcome of
study as concluded that 10 mg/day of Deprenyl delays the onset of disability associated with early Parkinson's disease
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that was otherwise untreated in contrast to 2000 IU/ day of tocopherol. Suppression of dopamine release result in
reduction of oxidative stress. By its action at D2 autoreceptors, found on Dopamine receptor agonists were considered
to be potentially neuroprotective. Certain agonists, such as Pramipexole, have hydroxylated benzyl ring structure and
may also act as direct antioxidants 16,17.So , a study, CALM-PD trial (Comparison of the agonist pramipexole with
levodopa on motor complications of Parkinson's disease) was carried out in order to compare Pramipexol with
levodopa18. Patients on Pramipexol showed less decrease in β-CIT uptake rather than those on levodopa alone.
Another trial named Ropinirole as Early Therapy versus L-dopa Positron Emission Tomography (REAL-PET ) trial
showed same results. A decrease in putaminal18 Fdopa uptake was found in ropinirole group versus levodopa group.
Drawbacks like extended washout of medications, lack of placebo control along with other limitations question the
neuroprotective role of Dopamine agonist as depicted by both mentioned study trials14,15. Rasagiline , Selegiline and
vitamin E are the agents used as antioxidant agents in many studies. Mechanism underlying is monoamine oxidase B
inhibition which leads to reduction in dopamine oxidation. Selegiline and Vitamin E neuroprotective effect in early PD
patients was tested by the DATATOP trial (Deprenyl and tocopherol antioxidative therapy of parkinsonism)20,21.
Results showed that as compared to patients given placebo, vitamin E did not show any improvement neither positively
affected selegiline’s effect while selegiline significantly delayed the time of onset of levodopa treatment. The limitation
of study is that selegiline improve PD symptoms by exerting mild symptomatic effect that improves motor symptoms in
PD. This created bias in study. To decrease the confounding effect of symptomatic efficacy, study was conducted on
Rasagiline which is a newer MAO-B inhibitor, more efficacious than selegiline. With antioxidant characteristics of its
metabolite. (FIGURE 5).
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END
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FIGURE 5 : The delayed-start design diagram .
One of the study with delayed start design was TEMPO study ( Rasagiline in Early Monotherapy for Parkinson's
Disease Outpatients). Patients were subjected to placebo or rasagiline for 6 months followed by another 6 months
treatment on Rasagiline 22. Results suggested that a long-lasting improvement is obtained through early treatment.
Limitation was short duration of study, and limited sizes of groups. A study, ADAGIO (Attenuation of Disease
Progression with Azilect Given Once-daily trial) with a larger sample size and extended duration was conducted for
analyzing these initial results but also turned out unsuccessful.In ADAGIO trial newly diagnosed patients with PD were
given once daily either 1 mg rasagiline, 2 mg rasagiline, or placebo 23 .Switching of placebo arm to the active
treatment arm was done after 9 months while continuing those patients on rasagiline on it for further 9
months.Results are shown in Figure 6 and 7.After 18 months, the 1 mg rasagiline treatment arm fulfilled all three
pre-specified endpoints which were considered to reflect a disease-modifying effect were fulfilled by 1 mg rasagiline
but not by 2 mg rasagiline after 18 months24. The reason for such difference is not known. Food and Drug
Administration (FDA) in the US did not approve for rasagiline as a disease-modifying therapy. A trial on Coenzyme Q10
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was carried out.Electron transport chain in mitochondria has a cofactor , Coenzyme Q 10 that has been shown to
reduce dopaminergic neurodegeneration in PD mouse models25.
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(P<0.001).

FIGURE 6: ADAGIO TRIAL: Rasagiline 1 mg Results
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FIGURE 7 : ADAGIO trial: Rasagiline 2 mg Results
CoQ10 used in doses 300 mg, 600 mg, or 1200 mg versus placebo was studied for 16 months or until levodopa
required26. Results showed reduction in UPDRS score in patients treated with CoQ10 treated patients as compared
to placebo with most of the benefit was on 1200 mg of CoQ10. As it did not meet the criteria for futility, a larger,
long-term study using high doses of CoQ10 versus placebo has recently been started. Another agent, Creatine was
also studied in a trial. Animal models has shown neuroprotective effect of creatine which functions to promote
mitochondrial ATP production27.Creatine versus placebo in early PD patients was compared and followed for two years
28. UPDRS score or β-CIT uptake failed to show any difference between the control and creatine groups. A large phase
III trial with different stages of PD is in progress. In literature, few trials using antiapoptotic agents are also mentioned
like TCH346 and CEP-1347. The propargylamine TCH346 inhibits the apoptotic process by inihibiting glycolytic enzyme
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glyceraldehyde-3-phosphate dehydrogenase (GAPDH) .A double-blind, randomized trial was carried out and followed
over 12 to 18 months, but unlike animal models 29,30 this study failed to show a significant difference in clinical
outcome31. Another trial , Parkinson Research Examination of CEP-1347 Trial (PRECEPT) was conducted although
terminated early due to futility on interim analysis, to assess the efficacy and safety of CEP 1347, inhibitor of mixed
lineage kinases inhibitor. It is also an anti-apoptotic factor that can activate the c-Jun N-terminal kinase (JNK) pathway
involved in cell death and has turned out promising in preclinical studies 32-34. Numerous trophic factors have also
been studied in an attempt to develop PD disease modifying therapy.These agents factors promote the nigral
dopaminagic neurons survival acting as neuroprotective in animal models 35-37. Glial-Derived Neurotrophic Factor
(GDNF) has been delivered so far primarily by direct infusion of the protein into the brain suggested to be effective in
smaller studies 38 but a larger controlled study involving was halted because of lack of efficacy 39. Serious
device-related adverse events and development of serum antibodies to GDNF was reported. Delivery of trophic factors
by gene transfer approaches is alternative to its direct infusion. 40. Recently neurturin, a neurotrophic factor related
to GDNF has been used 41,42. Motor function in MPTP-treated monkeys 43 and in 6- OHDA-treated rats found to be
improved by delivery of an adeno-associated viral (AAV-2) vector containing neurturin (CERE-120) 44, 45. 12 patients
with advanced PD tested for CERE-120 safety and found promising. 46Caution needed in interpretation of open - label
trials data .A larger double-blind study is in progress. Neuroimmunophilins, intracellular receptor proteins promote
neuronal growth independently of their immunosuppressive effects 47-49.This effect is shown in 6- OHDA and MPTP
animal models 50-52, although neurodegeneration has not been reduced in all PD animal models 53,54. In extension
study, the effects of continued (prior GDNF patients) or new (prior placebo patients) exposure to GDNF, given as
Intraputamenal glial cell line-derived neurotrophic factor (GDNF) were explored for another 40 weeks. Although, in
nonhuman primate Parkinson’s disease models55, GDNF is shown to have neuroprotective and neurorestorative effects
56,57
but as neuromodulating treatment failed to show a significant clinical benefit till date58,59. Drugs which are used in
other diseases have also been studied like pioglitazone. Patients with PD who were on regimen of rasagiline or
selegiline as stable treatment were randomly assigned with (1:1:1) to 15 mg/day pioglitazone, 45 mg/day pioglitazone,
or placebo and were followed from 2011 to 2013. Results were insignificant and further larger trial of pioglitazone is
not recommended. Despite well recognized anti-inflammatory and antiapoptotic actions of minocycline 60, experiments
failed to show beneficial effects. It was concluded that symptoms developed more rapidly and severely in minocycline
/MPTP-treated animals. With the advancement in disease pathogenesis,based on the thought that to replace
substantia Nigra pars compacta (SNc) dopamine neurons affected by the disease process, embryonic dopaminergic
cells could be transplanted into the brain, cell-based transplantation strategies were initiated. Despite the popularity
of stem cells among public, the stem cells found unsuccessful to provide further benefits versus fetal nigral dopamine
cells in animal models. In addition, these trials also have risk of tumourogenesis.
TABLE 1: PREVIOUS TRIALS FOR PARKINSONS DISEASE MODIFICATION

PREVIOUS CLIICAL TRIALS FOR DISEASE MODIFICATION IN PD
TARGETS/MECHANISM
OF ACTION

THERAPEUTIC AGENT

TRIAL

EARLYVERSUS LATE LEVODOPA USE
USE OF TO COPHEROL AND DEPRENYL

LEVODOPA 150 mg, 300 mg, 600 mg per day
DeprenyI (10 mg per day)
Vitamin E ( 2000 IU per day)
compared pramipexole with L-dopa
Selegiline,
Vitamin E,
Rasagiline.

ELLDOPA trial

TCH346
CEP-1347
Gilal-derived neurotrophic factor (GDNF)
Neurturin (CERE-120)
Neuroimmunophilins

PRECEPT trial

DOPAMINE RECEPTOR AGONISTS
ANTIOXIDANT THERAPIES

COENZYME Q10
CREATINE
ANTI-APOPTOTIC AGENTS
TROPHIC FACTORS

CALM-PD trial
DATATOP trial
TEMPO study
ADAGIO trial

PIOGLITAZONE IN EARLY PARKINSON�S
DISEASE
MINOCYCLINE
DOPAMINE CELL TRANSPLANTATION
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ONGOING PD MODIFICATION CLINICAL TRIALS
TRIALS /DRUG IN ADVANCED STAGES OF STUDY
Isradipine, currently approved as antihypertensive, is a dihydopyridine calcium channel blocker.It acts preferably on
Cav1.3 channels which are the calcium channels expressed in many regions of body including many areas of brain too.
Neuroprotection is shown in PD mouse models through substantia nigra pacemaker activity inhibition by CaV1.3
channel blockade. Isradipine causes blockade of calcium entry into brain cells thus preventing brain cell death.It has
also being studied for neuromodulation in PD. Urate is one of the main antioxidant found in plasma.Its precursor is
Inosine which ultimately has some neuroprotective effects. SURE-PD3 (Study of Urate Elevation in Parkinson's
Disease, Phase 3) is ongoing in people of 30 years ages .It was started in June 2016 and it has been estimated to
complete on October 31, 2019. Unfortunately, National Institute of Neurological Disorders and Stroke (NINDS)
announces early study closure of SURE-PD3 Trial , after an interim analysis showed futility.The trial was testing whether
a treatment that raises blood levels of the natural antioxidant urate (from ≤5.7 mg/dL to 7.1-8.0 mg/dL ) for two
years slows the rate of worsening in PD Movement disorder Society-Unified Parkinson's Disease Rating Scale
(MDS-UPDRS). Urate has antioxidant properties in substantia nigra pars compacta dopaminergic neurons in animal
models .In conclusion, whether inosine has disease-modifying potential or not remains to be evaluated. Deferiprone
act as a strong chelator of iron and is being studied. Exenitide is approved for Type 2 diabetes treatment. In animal
models neuroprotective, and neurorestorative effect is found which leads to learning, and memory, behavior and motor
function improvement 61. Exenitide ,exendin synthetic form and human glucagon –like peptide -1 naturally found
analogue. Oxidative and cellular stress activates the protein Abelson (c-Abl) , a non-receptor tyrosine kinase 62. C-Abl
has different location in the cell which affects its function.Actions includes parkin inactivation, , toxic elements
autophagy impairment and alpha synuclein aggregation, role in cellular adhesion and survival pathways in the cell
cytoplasm 63.By using 1-methyl-4phenylpyridinium and in vitro using MPTP toxin ,c-Abl can be activated 64,65. Its role
in the pathogenesis of PD and other α-synucleinopathies is established 66,67 (FIGURE 8) summarizes its role.Further
larger clinical trials of neuromodulation are recommended. Tyrosine kinase enzymes can be selectively inhibited by a
group of drugs labeled as Tyrosine kinase inhibitors (TKIs), a group of drugs inhibiting tyrosine kinase selectively 68
showed a neuroprotective potential in MPTP mouse models against dopaminergic toxins 69.
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FIGURE 8: Mechanism of action of c- ABL
Low doses of nilotinib over long periods enhance Alpha synuclein autophagic degradation 70. Another agent, bafetinib
prevent parkin inactivation and dopaminergic neuron loss as suggested by Imam et al. 71 Imatinib produced the similar
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neuroprotective effects but it had lower bioavailability in the brain leading to less potency. During the analysis, only one
patient developed a serious cardiac adverse event72. Various recommendations are given for nilotinib use 73. Care and
liver functions monitoring is needed 74. Although, no convincing evidence of its efficacy in PD patients has been found
yet but trials are ongoing 75. Restoration of dopaminergic deficits has also been considered. Off-target effects can be
minimized with oral dopamine replacement which can act by providing the regenerative treatments to the striatum. So
far, with varying success rate, different cell sources for transplantation in PD have now been investigated 76.Many
critical features of PD can be treated by such cell based approaches like use of human fetal ventral mesencephalon
(VM) tissue grafts in humans. The drawbacks include ethical and others such as unexpected insufficient fetal tissue
supply leading to unpromising results 76. Stem cells is now considered as the most likely approach of delivering a
clinically useful and cell-based ,clinically useful therapy for 77.The risk of tumour formation can be avoided by by
thorough investigation of safety, and proper surveillance. Another approach toward a regenerative treatment for PD
includes viral vectors. As per viral gene-delivery trials; Lentivirus vectors have much larger capacity for genetic cargo
than Adeno-associated virus (AAV).It can be used as are integrating viral vectors78 .ProSavin, a lentiviral product
carrying the genes for aromatic amino acid decarboxylase, tyrosine hydroxylase and cyclohydrolase-1. Although, a
phase I/II trial have shown its well tolerance but unfortunately, many patients experienced an increased on-medication
dyskinesias78. In United Kingdom and France, a further trial of OXB-102, a new version of ProSavin is near initiation.
For developing agent havng PD disease-modifying effect that targets alpha synuclein, various experimental approaches
are either have been investigated or are currently ongoing.
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Figure 6. Diagrammatic representation of alpha synuclein as target of drug.
RNA interference technologies can be used to obtain this goal. In RNA interference, synthetic ribonucleic acid (RNA)
molecules are introduced extrinsically which leads to messenger RNA (mRNA) degradation, ultimately triggering
selective post-transcriptional silencing of the α-synuclein gene. Rodent model using Lentiviral delivery of a short-hairpin
RNA (shRNA) offers support to this concept79. Direct infusion of a small-interfering RNA (siRNA) directed against
α-synuclein into the mouse hippocampus has also been shown80. Clenbuterol , β2-adrenergic receptor agonists (β2
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agonists) used in the asthma has been found to cause reduction in α-synuclein gene expression by 35% in a
neuroblastoma cell line and in rat cortical neurons. Moreover, it can cross the blood brain barrier which is a necessary
requirement for proposed treatment approaches 81. Active and passive immunotherapies have been shown capable of
targeting and degrading extracellular α-synuclein82. An active immunotherapy vaccine (AFFITOPE PD03A, AFFiRiS,
Austria) phase I clinical trial has recently been completed. AFFiRiS , a synthetically produced vaccine containing an
α-synuclein resembling peptide , has passed its safety testing in trial.Repeated subcutaneous injections of high dose
or low dose AFFITOPE PD03A showed cross reactivity against α-synuclein and immune response depending on the
dose against the peptide with increasing antibody titers over time. Other safe active immunotherapies in early PD
include PD01A. Passive immunotherapeutic agent, humanized monoclonal antibodies against α-synuclein PRX001
has also been tested. MEDI1341 for PD, additional immunotherapies targeting α-synuclein are under development. By
using intravenous injections, two antibody Infusion trials are there. The current ntravenous trials are Biogen (phase 2a)
and Roche (phase 2b). Despite the promising safety data, results as neuromodulating agent are insignificant. Both
chaperone-mediated autophagy and macroautophagy plays significant role in alpha-synuclein degradation pathways
83
. Rapamycin , an immunosuppressant and is a recently known macroautophagy inducer 84. Animal model of GBA1
(encoding for the lysosomal enzyme glucocerebrosidase) has shown to reduce alpha synuclein in mutation-associated
PD 85.Trehalose and the tricyclic antidepressant nortriptyline increases autophagy activity like several compounds
86,87 therefore are being considered for clinical trials. Trehalose, a naturally occurring disaccharide with the ability
to reduce protein aggregation as well as act via mammalian target of rapamycin for increased degradation86,87 .
Gaucher disease, a lysosomal storage disease results from homozygous mutation in Glucocerebrosidase 1 gene (GBA1
gene) which encodes for the enzyme β-glucocerebrosidase (GCase). Ongoing two clinical trials in PD patients aim to
correct abnormalities in the lysosomal environment in such patients. Patients, in the first phase II trial of MOVES-PD
(Multicenter pharmacOkinetics and interVEntional Study in Parkinson's Disease - MOVES-PD) , patients are
receiving a compound called GZ/SAR4026715. It inhibits the glycosphingolipids production which build up in cells in
PD patients with GBA1 mutations and are catabolized by GCase .Other clinical trials are under consideration as
potential treatment for GBA1 mutation-associated PD using ambroxol88, a Food and Drug
Administration(FDA)-approved mucolytic. Ambroxol facilitates the pathway of misfolded GCase to the lysosome through
its chaperone properties89.
REPURPOSING OF OTHER DRUGS
Drug repositioning /drug repurposing or drug reprofiling is the redevelopment of a drug for its use in a different disease.
Recent examples include Exanitide and Nilotinib in PD patients. Exenatide, a well known antidiabetic drug whereas
nilotinib , the chronic myelogenous leukemia treatment. Currently an ongoing trial to evaluate the safety and tolerability
of nilotinib in Parkinson's disease (NILO-PD) is in progress in the United States75. Statins has many mechanisms of
actions which are cholesterol-independent and mostly have neuroprotective potential including proinflammatory
molecules suppression & microglial activation, alpha -synuclein aggregation attenuation , endothelial nitric oxide
synthase stimulation ,adaptive immunity modulation , neurotrophic factors enhanced expression , and inhibition of
oxidative stress. An ongoing clinical trial has started in 2015 and with expected completion in 2020.It aims to
determine whether protection against chronic neurodegeneration is provided by Simvastatin or not 90.
TRIALS FOR TACKLE THE PROBLEM “AT SOURCE”
Gut bacteria produce metabolites which have been identified to have a link with brain inflammation. A trial of giving PD
patients, encapsulated fecal transplants from healthy individuals is under consideration. Although this approach has
limitation and can contribute to ongoing neurodegeneration with time. To evaluate Fecal Microbiota Transplant (FMT)
in PD management, a clinical is ongoing 91.
NANOTECHNOLOGY:
Nanoscience intends towards material manipulation at sub-atomic or atomic levels whose characteristics differ
markedly as compared to the bulk matter whereas nanotechnology intends to utilize these manipulated materials for
purposes like characterizing, designing and formation of improved structure, devices and systems with designated
size and shape (1-100 nm) for various purposes92. Graphene quantum dots (GQDs) is emerging as showing some
promise 93. GQDs can block the formation of alpha synuclein fibrils and promote their disaggregation by interation with
fibrils of alpha synuclein. This technology carries great promise for future health management perspectives. Although,
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nanotechnology accounts only 5% in publications worldwide but this technology is at its budding level with the few
products in the market 94.
OTHER AGENTS
DNL201 is a Leucine-rich repeat kinase 2 (LRRK2) inhibitor being tried in Parkinson’s patients with the genetic
mutation (LRRK2). Another such drug, DNL151 is being evaluated in the Netherlands96
Coffee drinking is long been known to be protective against PD97. Theoretically, Caffeine effects alpha-synuclein
aggregation as well as on inflammatory processes in the gut. Unfortunately, clinical evidence of caffeine therapy in PD
is lacking. The symptomatic effect of 200 to 400 mg per day caffeine in PD in a placebo-controlled randomized trial
of 6 week showed improvement.98 Further studies are needed. Nicotine role as a potential treatment for PD has been
evaluated previously 99. Numerous studies continued to show that PD is less prevalent among smokers than those who
never smoked 100,101.
CELL SURVIVAL/DEATH
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Figure 7 : PD progression impact by various agents
Nicotine experimentally did prevents or slow down neurodegeneration by up-regulating anti-apoptotic protein 102.
Moreover, cytochrome P450 enzymes family is also induced for detoxification of neurotoxin. Protection against
toxin-induced nigrostriatal degeneration in a PD animal model is also provided 103. A trial named Disease-modifying
Potential of Transdermal NICotine in Early Parkinson's Disease (NIC-PD) has been done. The study was
conducted from 2012 to 2016. In contrary to the hypothesis it was found that nicotine may accelerate the disease as
shown by worsening of UPDRS scores versus placebo 104
NATURAL COMPOUNDS
Newer researches aim for the identification of natural compounds which can of halt or slow down the
neurodegeneration for example Polyphenols and flavonoids. Extracted chiefly from plants and microorganisms contain
biological agents acting on multiple targets105. Currently, the data is scares further studies desired.
EXERCISE AND PHYSICAL THERAPY
Physical exercise, a well-recognized non-pharmacological form of PD treatment over 50 years 106 it results in
improvement in functional capacity, strength, walking and balance of the patients 107,108.In rats , treadmill exercise
effect were examined 109 and the results showed modulation of various factors including Brain-Derived Neurotrophic
Factor (BDNF) in the basal ganglia ,changes in mitochondrial function balance and coordination. Moreover, other
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animal model studies suggested that brain plasticity is also affected which in turn leads to neuromodulation.These are
facilitated by Vascular Endothelial Growth Factor (VEGF) the Glial cell line-Derived Neurotrophic Factor (GDNF) release
109-111
.There is also decreased formation of Reactive Oxygen Species (ROS) formation and reduced oxidative stress 112.
TABLE.5: RECENT CLINICAL TRIALS FOR DISEASE MODIFICATION IN PD
ONGOING CLINICAL TRIALS
TARGETS/MECHANISM OF ACTIONS

THERAPEUTIC AGENT

TRIALS

DOPAMINERGIC DEFICITS RESTORATIONS
GENE DELIVERY APPROACHES
TRIALS USING ALPHA-SYNUCLEINAS A
THERAPEUTIC TARGET
Alpha-Synuclein Production reduction
Extracellular a-synuclein degradation
Immunotherapies

AUTOPHAGY ENHANCEMENT
OTHER DRUGS REPURPOSING

�AT SOURCE� PROBLEM
CONFRONTATION
IMMUNOMODULATION TRIALS
NANOTECHNOLOGY

OTHER AGENTS
URATE ELEVATION
CAFFENE
NICOTINE
LRRK2 INHIBITOR
NATURAL COMPOUNDS

ProSavin
Clenbuterol
active immunotherapy vaccine (AFFITOPE
PD03A, AFFiRiS, Austria)
PD01A
PRX001
a-synuclein antibody MEDI1341 for PD

Rapamycin
Trehalose and Nortriptyline
GBA1 mutation and Ambroxol
Exanitide
Nilotinib
Simvastatin
Defiriprone
Isradipine
Gut microbiome

two antibody infusion trials
Biogen (phase 2a) and
Roche (phase 2b).

MOVES-PD
(NILO-PD)

Graphene quantum dots (GQDs)

SURE-PD

Inosine

(NIC-PD)
DNL201, DNL151
Polyphenols and flavonoids, saffron, turmeric,
ginkgo, green tea/black tea

CONCLUSION
Disease modification in PD remains an important but difficult to achieve target. Despite too many trials no agent has
been approved as Parkinson disease modifying agent yet. Once this goal will be achieved successfully, neuroprotective
treatment could transform PD patients’ lives to a problem that can be managed rather than having a progressive and
disabling disease. Most important barriers for development of disease modification drugs include PD pathogenesis
knowledge limitations, lacking strategies and the study design for disease progression study. Encouragingly, there has
been an increasing interest in understanding and treating PD which hopefully will lead to developing better therapies
for PD. It is expected that further research focused on better elaboration at molecular level PD pathology will lead to
the fruitful outcomes in understanding the main defining pathways of PD mechanisms; ultimately the efforts to develop
disease modifying treatment can be advanced soon.
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